

Application No. 10/006,869

REMARKS

Further to the Amendment filed with the Request for Continued Examination (RCE) dated November 4, 2004, claims 8 and 105-117 are currently under examination in the Application. As discussed by telephone with Examiner Moran on January 19, 2005, the above amendment directs the claims more particularly to the subject matter specifically elected for prosecution, that is, peptide modulating agents having the sequence CDAEC (SEQ ID NO: 910). Applicants respectfully request that the above amendment to claim 8 be entered prior to examination of the RCE on the merits.

The Commissioner is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment, to our Deposit Account No. 19-1090.

All of the claims remaining in the application are now believed to be in condition for allowance. Favorable consideration is respectfully requested.

Respectfully submitted,

SEED Intellectual Property Law Group PLLC



Jeffrey Hundley, Ph.D., Patent Agent
Registration No. 42,676

JEH:tt

Enclosure:
Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

553418_1.DOC